Di-enzymatic Chimeric Endolysin Synergistic Peptidoglycan Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial agents face challenges in effectively targeting and lysing Gram-positive bacterial cells, particularly in cases of antibiotic-resistant strains, due to limitations in specificity and efficiency.
Innovation Solution
Development of a di-enzymatic chimeric endolysin with a modular structure, comprising a primary and secondary enzymatic active domain and a cell wall binding domain, which synergistically cleaves peptidoglycan bonds in bacterial cell walls, enhancing bacteriolytic activity and broadening the host range.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial agents are used, then they can target bacterial cells, but they fail to effectively lyse antibiotic-resistant strains due to limitations in specificity and efficiency
Solution Approach 1:
The patent combines two different enzymatic active domains (N-terminal and C-terminal domains) into a single chimeric endolysin molecule. The N-terminal domain provides one type of peptidoglycan cleavage activity while the C-terminal domain provides complementary cleavage activity, creating a synergistic effect that dramatically enhances bacteriolytic activity against resistant strains including Streptococcus pneumoniae.
Solution Approach 2:
The chimeric endolysin is designed with multiple functional domains that enable it to target and cleave different types of peptidoglycan bonds through synergistic action. This multi-functional design allows the single molecule to effectively lyse a broad spectrum of Gram-positive bacterial strains, including antibiotic-resistant strains, thereby achieving universality across different host ranges.
2Reliability
If a single enzymatic domain is used, then the structure is simple, but the bacteriolytic activity is insufficient against resistant strains
Solution Approach 1:
The patent merges two distinct enzymatic active domains into one chimeric molecule, with the N-terminal domain and C-terminal domain working synergistically. This combination creates enhanced bacteriolytic activity that overcomes the limitations of single-domain enzymes against antibiotic-resistant strains, while maintaining a manageable modular structure.
3Productivity
If conventional endolysins are used, then they have limited activity, but increasing the enzymatic power may reduce specificity
Solution Approach 1:
The chimeric endolysin incorporates a cell wall binding domain with a specific recognition sequence that provides localized specificity for binding to bacterial cell walls. This targeted binding ensures that the enhanced enzymatic power of the dual catalytic domains is directed specifically at bacterial cells, maintaining high specificity even as overall lytic activity increases through synergistic enzymatic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The di-enzymatic chimeric endolysin demonstrates significantly increased activity against resistant bacterial strains, including Streptococcus pneumoniae, with a 100-fold increase in vitro activity and improved in vivo efficacy, offering a potential alternative to conventional antibiotics.
Implementation Method 1
a primary enzymatic active domain disposed at an N-terminus end of the di-enzymatic chimeric endolysin, the primary enzymatic active domain comprising a primary protein sequence and that cleaves a glycosidic, peptide, or amide bond of the peptidoglycan in a cell wall of a cell
Implementation Method 2
a secondary enzymatic active domain disposed at a C-terminus end of the di-enzymatic chimeric endolysin, the secondary enzymatic active domain comprising a secondary protein sequence and that, in combination with the primary enzymatic active domain, synergistically cleaves glycosidic, peptide, or amide bonds in the peptidoglycan in the cell wall
Implementation Method 3
a cell wall binding domain: comprising a recognition sequence; chemically attached to the primary protein sequence and the secondary protein sequence, sequentially interposed between the primary protein sequence and the secondary protein sequence, and that binds to a cell wall
Data Source
AI summary
A di-enzymatic chimeric endolysin includes a primary enzymatic active domain including a primary protein sequence and that cleaves a glycosidic, peptide, or amide bond; a secondary enzymatic active domain disposed at a C-terminus end of the di-enzymatic chimeric endolysin and including a secondary protein sequence that, in combination with the primary enzymatic active domain, synergistically cleaves glycosidic, peptide, or amide bonds in a peptidoglycan; a cell wall binding domain including a recognition sequence that is sequentially interposed between the primary protein sequence and the secondary protein sequence and that binds to a cell wall; and a tertiary structure such that the primary enzymatic active domain faces and opposes the secondary enzymatic active domain in the di-enzymatic chimeric endolysin for synergistic cleavage of the peptidoglycan.